Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Borderline Resectable Pancreatic Adenocarcinoma”

93 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 93 results

Testing effectiveness (Phase 2)Not Yet RecruitingNCT07616362
What this trial is testing

Personalize (Signature Driven) Neoadjuvant Chemotherapy Trial for Patients With Resectable Borderline Pancreatic Ductal Adenocarcinoma.

Who this might be right for
Borderline Resectable Pancreatic Ductal Adenocarcinoma
Federation Francophone de Cancerologie Digestive 110
Testing effectiveness (Phase 2)Not Yet RecruitingNCT05562297
What this trial is testing

Neoadjuvant/Adjuvant Sintilimab, Nab-paclitaxel, and Gemcitabine for Resectable/Borderline Resectable Pancreatic Cancer

Who this might be right for
Pancreatic Cancer, Stage IBPancreatic Cancer, Stage IIAPancreatic Cancer, Stage IIB+1 more
Shanghai Zhongshan Hospital 50
Testing effectiveness (Phase 2)Ended earlyNCT01897454
What this trial is testing

Gemcitabine Hydrochloride, and Radiation Therapy in Patients With Borderline Resectable Pancreatic Cancer

Who this might be right for
Pancreatic AdenocarcinomaStage IIA Pancreatic CancerStage IIB Pancreatic Cancer+1 more
Albert Einstein College of Medicine 23
Testing effectiveness (Phase 2)Ended earlyNCT01431794
What this trial is testing

Gemcitabine + Nab-paclitaxel With LDE-225 (Hedgehog Inhibitor) as Neoadjuvant Therapy for Pancreatic Adenocarcinoma

Who this might be right for
Pancreatic Ductal Adenocarcinoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 23
Not applicableStudy completedNCT03266757
What this trial is testing

Borderline Resectable or Resectable or Advanced Pancreatic Adenocarcinoma

Who this might be right for
Pancreatic Adenocarcinoma
Hellenic Society of Medical Oncology 200
Testing effectiveness (Phase 2)Looking for participantsNCT05851924
What this trial is testing

NALIRIFOX in Combination With Radiation Therapy in People With Pancreatic Ductal Adenocarcinoma (PDAC)

Who this might be right for
Pancreatic Ductal Adenocarcinoma
Memorial Sloan Kettering Cancer Center 60
Testing effectiveness (Phase 2)Active Not RecruitingNCT02446093
What this trial is testing

Neoadjuvant CAN-2409 in Combination With Chemoradiation or SBRT for Borderline Resectable Pancreatic Adenocarcinoma

Who this might be right for
Borderline Resectable Pancreatic Adenocarcinoma
Candel Therapeutics, Inc. 54
Very early researchStudy completedNCT03153410
What this trial is testing

Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas

Who this might be right for
Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 11
Testing effectiveness (Phase 2)UnknownNCT01676259
What this trial is testing

SiG12D LODER in Combination With Chemotherapy in Patients With Locally Advanced Pancreatic Cancer

Who this might be right for
Pancreatic Ductal AdenocarcinomaPancreatic Cancer
Silenseed Ltd 80
Not applicableUnknownNCT02781012
What this trial is testing

Project Survival-Prospective Biomarker Discovery

Who this might be right for
Pancreatic NeoplasmsPancreatic CancerPancreatitis+2 more
Pancreatic Cancer Research Team 436
Testing effectiveness (Phase 2)Ended earlyNCT01359007
What this trial is testing

FOLFIRINOX in Patients With Inoperable Pancreatic Cancer

Who this might be right for
Adenocarcinoma of Pancreas
University of Oklahoma 5
Not applicableStudy completedNCT05888129
What this trial is testing

Clinical Outcomes of Surgery After Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Cancer

Who this might be right for
Postoperative Complications
Asan Medical Center 1
Early research (Phase 1)Looking for participantsNCT06141031
What this trial is testing

Radiotherapy in Combination With TTI-101 in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma

Who this might be right for
Pancreatic Cancer
Washington University School of Medicine 18
Testing effectiveness (Phase 2)Study completedNCT05262855
What this trial is testing

Study of [68Ga]FAPI-46 PET in Patients With Pancreatic Ductal Carcinoma

Who this might be right for
PDAC - Pancreatic Ductal AdenocarcinomaFAP
SOFIE 63
Testing effectiveness (Phase 2)Active Not RecruitingNCT04539808
What this trial is testing

NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer

Who this might be right for
Pancreatic AdenocarcinomaStage 0 Pancreatic Cancer American Joint Committee on Cancer v8Stage I Pancreatic Cancer American Joint Committee on Cancer v8+2 more
OHSU Knight Cancer Institute
Large-scale testing (Phase 3)Looking for participantsNCT06714604
What this trial is testing

Standard or Prolonged Neoadjuvant Chemotherapy Before Surgery for BR/LAPC

Who this might be right for
Locally Advanced Pancreatic AdenocarcinomaBorderline Resectable Pancreatic CarcinomaPancreas Cancer+3 more
Sahlgrenska University Hospital 432
Testing effectiveness (Phase 2)Study completedNCT02749136
What this trial is testing

Neoadjuvant Modified FOLFIRINOX in Borderline Resectable Pancreatic Cancer

Who this might be right for
Pancreatic Adenocarcinoma
Asan Medical Center 44
Large-scale testing (Phase 3)UnknownNCT04617821
What this trial is testing

AG vs mFOLFIRINOX as Neoadjuvant Therapy for Borderline Reseactable and Locally Advanced Pancreatic Cancer

Who this might be right for
Borderline Resectable Pancreatic CancerLocally Advanced Pancreatic Adenocarcinoma
Fudan University 300
Not applicableUnknownNCT05489458
What this trial is testing

Predictive Factors for Resection and Survival in Type A Borderline Resectable Pancreatic Ductal Adenocarcinoma Patients After Neoadjuvant Therapy

Who this might be right for
Carcinoma, Pancreatic Ductal
BUSQUETS, JULI 100
Testing effectiveness (Phase 2)WithdrawnNCT03038477
What this trial is testing

Durvalumab in Patients With BR PDA Following Neoadjuvant Therapy and Successful Surgical Resection

Who this might be right for
Pancreatic Cancer
University of Colorado, Denver
Load More Results
42